Saturday, October 3, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 28, 2026

Meta Reports Fourth Quarter and Full Year 2025 Results

View original at finance.yahoo.com
Meta Reports Fourth Quarter and Full Year 2025 Results MENLO PARK, Calif., Jan. 28, 2026 /PRNewswire/ -- Meta Platforms, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Continue to monitor legal and regulatory headwinds in EU and US that could significantly impact business and financial results

    80% confidence

  • Looking forward to advancing personal superintelligence for people around the world in 2026

    80% confidence

  • 2026 capital expenditures expected to be in the range of $115-135 billion, driven by Meta Superintelligence Labs efforts

    80% confidence

  • Majority of expense growth will be driven by infrastructure costs, including third-party cloud spend, higher depreciation, and higher infrastructure operating expenses

    80% confidence

  • Absent any changes to tax landscape, expect full year 2026 tax rate to be 13-16%

    80% confidence

  • First quarter 2026 total revenue expected to be in the range of $53.5-56.5 billion

    80% confidence

  • We had strong business performance in 2025

    80% confidence

  • Full year 2026 total expenses expected to be in the range of $162-169 billion

    80% confidence

  • Absent the valuation allowance charge as of enactment date, full year 2025 effective tax rate would have decreased by 17 percentage points to 13%

    80% confidence

  • Despite meaningful step up in infrastructure investment, in 2026 we expect to deliver operating income that is above 2025 operating income

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com